| Code | CSB-RA006163MB10HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to JS-007, designed for research targeting CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4), a critical immune checkpoint receptor expressed primarily on T cells. CTLA4 functions as a negative regulator of T-cell activation by competing with the costimulatory receptor CD28 for binding to B7 ligands (CD80/CD86) on antigen-presenting cells. This interaction delivers inhibitory signals that dampen immune responses and maintain peripheral tolerance. Dysregulation of CTLA4-mediated immune suppression is implicated in various pathological conditions, including autoimmune diseases where reduced CTLA4 function leads to excessive immune activation, and cancer where tumor cells exploit this pathway to evade immune surveillance.
JS-007 is a therapeutic antibody developed for modulating CTLA4-mediated immune responses, and this biosimilar provides researchers with a valuable tool for investigating immune checkpoint mechanisms, T-cell biology, and immunotherapy strategies. The antibody enables studies of CTLA4 expression patterns, protein interactions, and functional consequences of checkpoint modulation in preclinical models of autoimmunity, transplantation, and oncology.
There are currently no reviews for this product.